PL2440242T3 - Kompozycje adiuwantowe zawierające niejonowy środek izotonizujący - Google Patents

Kompozycje adiuwantowe zawierające niejonowy środek izotonizujący

Info

Publication number
PL2440242T3
PL2440242T3 PL10721036T PL10721036T PL2440242T3 PL 2440242 T3 PL2440242 T3 PL 2440242T3 PL 10721036 T PL10721036 T PL 10721036T PL 10721036 T PL10721036 T PL 10721036T PL 2440242 T3 PL2440242 T3 PL 2440242T3
Authority
PL
Poland
Prior art keywords
isotonicity agent
adjuvant compositions
ionic isotonicity
ionic
adjuvant
Prior art date
Application number
PL10721036T
Other languages
English (en)
Inventor
Veronique Henderickx
Dominique Ingrid Lemoine
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2440242(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL2440242T3 publication Critical patent/PL2440242T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10721036T 2009-06-10 2010-06-08 Kompozycje adiuwantowe zawierające niejonowy środek izotonizujący PL2440242T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
PCT/EP2010/058017 WO2010142685A1 (en) 2009-06-10 2010-06-08 Adjuvant compositions comprising a non-ionic isotonicity agent
EP10721036.1A EP2440242B1 (en) 2009-06-10 2010-06-08 Adjuvant compositions comprising a non-ionic isotonicity agent

Publications (1)

Publication Number Publication Date
PL2440242T3 true PL2440242T3 (pl) 2014-11-28

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10721036T PL2440242T3 (pl) 2009-06-10 2010-06-08 Kompozycje adiuwantowe zawierające niejonowy środek izotonizujący

Country Status (31)

Country Link
US (2) US20120087976A1 (pl)
EP (1) EP2440242B1 (pl)
JP (3) JP5647677B2 (pl)
KR (1) KR101473686B1 (pl)
CN (2) CN104367997B (pl)
AU (1) AU2010257538B2 (pl)
BR (1) BRPI1012890B1 (pl)
CA (1) CA2764421C (pl)
CL (1) CL2011003113A1 (pl)
CO (1) CO6440528A2 (pl)
CY (1) CY1115522T1 (pl)
DK (1) DK2440242T3 (pl)
DO (1) DOP2011000346A (pl)
EA (1) EA024074B1 (pl)
ES (1) ES2494442T3 (pl)
GB (1) GB0910046D0 (pl)
HR (1) HRP20140792T1 (pl)
IL (1) IL216231A0 (pl)
MA (1) MA33412B1 (pl)
MX (1) MX2011013162A (pl)
MY (1) MY159819A (pl)
NZ (1) NZ596503A (pl)
PE (1) PE20120319A1 (pl)
PL (1) PL2440242T3 (pl)
PT (1) PT2440242E (pl)
RS (1) RS53550B1 (pl)
SG (1) SG176638A1 (pl)
SI (1) SI2440242T1 (pl)
SM (1) SMT201400134B (pl)
UA (1) UA104888C2 (pl)
WO (1) WO2010142685A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668775T3 (es) 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
MX355836B (es) 2010-08-20 2018-05-02 Chugai Pharmaceutical Co Ltd Composicion que comprende compuestos tetraciclicos.
DK2651436T3 (da) * 2010-12-14 2016-06-20 Glaxosmithkline Biologicals Sa Mycobakterie antigen sammensætning.
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
CA2943190A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
EP3135671B1 (en) 2014-04-25 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Novel crystal of tetracyclic compound
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
EP3551222B1 (en) * 2016-12-07 2024-08-07 GlaxoSmithKline Biologicals SA Process for making a liposome composition comprising a saponin
AU2018258070A1 (en) 2017-04-25 2019-10-24 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018220553A1 (en) 2017-05-30 2018-12-06 Glaxosmithkline Biologicals Sa Methods for manufacturing a liposome encapsulated rna
WO2019079160A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
WO2019106192A1 (en) * 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
BR112020010635A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. extração de saponina
CN112384223B (zh) 2018-06-29 2024-08-27 中外制药株式会社 含有难溶性碱性药剂的药物组合物
WO2020050241A1 (ja) 2018-09-04 2020-03-12 中外製薬株式会社 ４環性化合物の製造方法
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP7640473B2 (ja) * 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CA3148928A1 (en) * 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
AU2024237452A1 (en) * 2023-03-15 2025-10-23 United Immunity, Co., Ltd. Lipid particle
WO2025180443A1 (en) * 2024-02-29 2025-09-04 Immunadd Inc. Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
HK1039072A1 (zh) * 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1829887B1 (en) * 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Cpg single-strand deoxynucleotides for use as adjuvant
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR20090101313A (ko) 2007-01-15 2009-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
MX2009007572A (es) 2007-01-15 2009-10-13 Glaxosmithkline Biolog Sa Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
KR101238795B1 (ko) * 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
ES2494442T3 (es) 2014-09-15
AU2010257538A1 (en) 2011-12-08
CN104367997A (zh) 2015-02-25
MY159819A (en) 2017-02-15
MX2011013162A (es) 2012-01-30
GB0910046D0 (en) 2009-07-22
NZ596503A (en) 2013-08-30
CL2011003113A1 (es) 2012-08-31
CY1115522T1 (el) 2017-01-04
JP2016193912A (ja) 2016-11-17
AU2010257538B2 (en) 2016-10-20
RS53550B1 (sr) 2015-02-27
CA2764421A1 (en) 2010-12-16
DOP2011000346A (es) 2012-01-15
JP2012529464A (ja) 2012-11-22
CN102458457B (zh) 2015-05-20
KR101473686B1 (ko) 2014-12-18
US20120087976A1 (en) 2012-04-12
EA024074B1 (ru) 2016-08-31
IL216231A0 (en) 2012-01-31
SMT201400134B (it) 2014-11-10
WO2010142685A1 (en) 2010-12-16
US20180021417A1 (en) 2018-01-25
JP5977789B2 (ja) 2016-08-24
KR20120031497A (ko) 2012-04-03
EP2440242A1 (en) 2012-04-18
PT2440242E (pt) 2014-08-29
SG176638A1 (en) 2012-01-30
JP6261647B2 (ja) 2018-01-17
MA33412B1 (fr) 2012-07-03
UA104888C2 (uk) 2014-03-25
EP2440242B1 (en) 2014-06-25
JP5647677B2 (ja) 2015-01-07
CN102458457A (zh) 2012-05-16
CO6440528A2 (es) 2012-05-15
CN104367997B (zh) 2019-01-22
DK2440242T3 (da) 2014-09-01
SI2440242T1 (sl) 2014-09-30
HRP20140792T1 (hr) 2014-10-10
PE20120319A1 (es) 2012-04-16
BRPI1012890B1 (pt) 2022-03-22
BRPI1012890A2 (en) 2018-02-27
CA2764421C (en) 2016-12-06
EA201190286A1 (ru) 2012-06-29
JP2015042646A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
SG176638A1 (en) Adjuvant compositions comprising a non-ionic isotonicity agent
PL2837383T3 (pl) Środek indukujący odporność
ZA200904935B (en) Benefit agent delivery compositions
IL205915A0 (en) Tapentadol compositions
ZA201005761B (en) Encapsulated benefit agent
PL2393476T3 (pl) Kompozycje resweratrolu
IL220526A0 (en) Kokumi-imparting agent
IL220527A0 (en) Kokumi-imparting agent
EP2420244A4 (en) MEANS TO PROMOTE FATTY CHANGE
EP2371938A4 (en) surfactant
PL2414499T3 (pl) Środek czyszczący
IL242592A (en) Immunogenic compounds
GB0919210D0 (en) Formulations
PL2414498T3 (pl) Środek czyszczący
ZA201006796B (en) Surfactant compositions
ZA201106842B (en) Sanitizer formulations
ZA201100635B (en) Sustained release pharmaceutical compositions comprising quetiapine
GB0920846D0 (en) Defenin inducing agent
EP2252326A4 (en) VACCINE COMPOSITIONS
IL209462A0 (en) Opiorphin for use as a psychotimulant agent
PH12012501255A1 (en) Sustained release formulation
GB0917792D0 (en) Delivery agent
PL2414495T3 (pl) Środek czyszczący do podłóg
HK1162974A (en) Adjuvant compositions comprising a non-ionic isotonicity agent
GB0920151D0 (en) Contrast agent compositions